Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Summary of Financial Information with Respect to Reportable Segments

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

	Year Ended December 31,
	2021			2020			2019
Segment revenues:
Software	$	113,236		$	92,530		$	66,735
Drug discovery		24,695			15,565			18,808
Total segment revenues	$	137,931		$	108,095		$	85,543
Segment gross profit:
Software	$	86,741		$	74,527		$	53,089
Drug discovery		(21,121	)		(11,055	)		(3,996	)
Total segment gross profit		65,620			63,472			49,093
Unallocated:
Research and development		(90,904	)		(64,695	)		(39,404	)
Sales and marketing		(22,150	)		(17,795	)		(21,364	)
General and administrative		(64,009	)		(41,898	)		(27,040	)
(Loss) gain on equity investments		(1,781	)		4,108			943
Change in fair value		11,359			28,263			9,922
Interest income		1,057			2,253			1,878
Income tax (expense) benefit		(411	)		(345	)		291
Consolidated net loss	$	(101,219	)	$	(26,637	)	$	(25,681	)

Schedule of Revenues by Geographic Area

The following table sets forth revenues by geographic area for the years ended December 31, 2021, 2020, and 2019:

	Year Ended December 31,
	2021		2020		2019
United States	$	90,398	$	60,737	$	47,622
Europe		27,810		24,370		17,504
Japan		8,565		14,558		14,367
Rest of World		11,158		8,430		6,050
	$	137,931	$	108,095	$	85,543